TIMOTHY ONEILL: Open Payments
NPI 1831161124 · MINDEN, NV. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$489 in 34 payments from 10 companies in 2025. Trend: 2023 $310 · 2024 $430 · 2025 $489
Food & beverage: $489
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 21 | $226 |
| ABBVIE INC. | 3 | $76 |
| Lilly USA, LLC | 2 | $32 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $32 |
| Esperion Therapeutics, Inc. | 1 | $24 |
| Xeris Pharmaceuticals, Inc. | 1 | $24 |
| Tanabe Pharma America, Inc. | 1 | $21 |
| Astellas Pharma US Inc | 1 | $21 |
| PFIZER INC. | 1 | $16 |
| GlaxoSmithKline, LLC. | 1 | $16 |
Products named: Ozempic, Rybelsus, VRAYLAR, MOUNJARO, CAPLYTA, Wegovy, NEXLETOL, GVOKE HYPOPEN.
Industry payments across NV — which companies pay providers there.
